Evidence on longer-term effects

DXM FAQ 1997: selective audit by topic

Animal experiments, MRI findings and the history of White’s withdrawal of his claims, considered separately.

Neurotoxicity: distinguish the types of evidence

Animal experiments, human MRI associations and claims of specific neuronal damage require separate interpretation. In 2004, White withdrew claims from his 1998 neurotoxicity text.

Clarified

According to the 2026 audit · edition

Evidence and limitations

What was examined: Carliss and Tran examined different administration routes and endpoints in rats. Qiu compared MRI findings in people dependent on DXM and a control group. White’s response records withdrawal of his earlier conclusions.

Limits of the conclusion: Transferring animal pathology to humans requires evidence. MRI associations allow several explanations; Olney lesions in humans after DXM have not been established in the reviewed sources.

Sources: Carliss — oral DXM in rats Tran — cellular changes in rats White — withdrawal of neurotoxicity claims Qiu — MRI in DXM dependence

Historical paraphrase · FAQ 4.0 · 1997 · §6.3.1 The FAQ discusses reports of lasting impairment and their resemblance to descriptions of Olney lesions. White later strengthened these claims in a separate text.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §6.3.1 · NMDA Antagonist Neurotoxicity (Olney's Lesions)

Sources for this topic
  1. Carliss — oral DXM in rats — PubMed abstract
  2. Tran — cellular changes in rats — PubMed abstract
  3. White — withdrawal of neurotoxicity claims — Historical archive

    The author’s 2004 response withdrawing his earlier claims was read.

  4. Qiu — MRI in DXM dependence — PubMed abstract

All update topics · Review coverage

Reference

Open the source and related combinations →